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Summary
Background Xerostomia is the most common late side-eﬀ ect of radiotherapy to the head and neck. Compared with 
conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We 
assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia.
Methods We undertook a randomised controlled trial between Jan 21, 2003, and Dec 7, 2007, that compared 
conventional radiotherapy (control) with parotid-sparing IMRT. We randomly assigned patients with histologically 
conﬁ rmed pharyngeal squamous-cell carcinoma (T1–4, N0–3, M0) at six UK radiotherapy centres between the two 
radiotherapy techniques (1:1 ratio). A dose of 60 or 65 Gy was prescribed in 30 daily fractions given Monday to 
Friday. Treatment was not masked. Randomisation was by computer-generated permuted blocks and was stratiﬁ ed 
by centre and tumour site. Our primary endpoint was the proportion of patients with grade 2 or worse xerostomia 
at 12 months, as assessed by the Late Eﬀ ects of Normal Tissue (LENT SOMA) scale. Analyses were done on an 
intention-to-treat basis, with all patients who had assessments included. Long-term follow-up of patients is ongoing. 
This study is registered with the International Standard Randomised Controlled Trial register, number 
ISRCTN48243537.
Findings 47 patients were assigned to each treatment arm. Median follow-up was 44·0 months (IQR 30·0–59·7). Six 
patients from each group died before 12 months and seven patients from the conventional radiotherapy and two from 
the IMRT group were not assessed at 12 months. At 12 months xerostomia side-eﬀ ects were reported in 73 of 
82 alive patients; grade 2 or worse xerostomia at 12 months was signiﬁ cantly lower in the IMRT group than in the 
conventional radiotherapy group (25 [74%; 95% CI 56–87] of 34 patients given conventional radiotherapy vs 15 [38%; 
23–55] of 39 given IMRT, p=0·0027). The only recorded acute adverse event of grade 2 or worse that diﬀ ered 
signiﬁ cantly between the treatment groups was fatigue, which was more prevalent in the IMRT group (18 [41%; 
99% CI 23–61] of 44 patients given conventional radiotherapy vs 35 [74%; 55–89] of 47 given IMRT, p=0·0015). At 
24 months, grade 2 or worse xerostomia was signiﬁ cantly less common with IMRT than with conventional radiotherapy 
(20 [83%; 95% CI 63–95] of 24 patients given conventional radiotherapy vs nine [29%; 14–48] of 31 given IMRT; 
p<0·0001). At 12 and 24 months, signiﬁ cant beneﬁ ts were seen in recovery of saliva secretion with IMRT compared 
with conventional radiotherapy, as were clinically signiﬁ cant improvements in dry-mouth-speciﬁ c and global quality 
of life scores. At 24 months, no signiﬁ cant diﬀ erences were seen between randomised groups in non-xerostomia late 
toxicities, locoregional control, or overall survival.
Interpretation Sparing the parotid glands with IMRT signiﬁ cantly reduces the incidence of xerostomia and leads to 
recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT 
in squamous-cell carcinoma of the head and neck.
Funding Cancer Research UK (CRUK/03/005).
Introduction
Radiotherapy is the main non-surgical treatment for 
squamous-cell carcinoma of the head and neck (HNSCC).1  
High rates of local tumour control can be achieved with 
5-year survival greater than 80% for stage 1 and 2 and 
60–70% for stage 3 and 4 tumours;2 however, long-term 
late sequelae of radiotherapy are highly prevalent and 
have severe adverse eﬀ ects on quality of life (QoL).3,4 
Radiation-induced xerostomia is the most commonly 
reported late side-eﬀ ect of radiotherapy to the head and 
neck. Lack of saliva aﬀ ects speech and swallowing and 
can accelerate dental caries.5 
Intensity-modulated radiotherapy (IMRT) is a 
conformal radiotherapy technique that can spare the 
major salivary glands. Small phase 2 studies have shown 
that a reduction in radiation to the parotid glands (to 
24–26 Gy) through parotid-sparing IMRT aids recovery of 
saliva ﬂ ow.6–8 We report results of the ﬁ rst multicentre 
randomised controlled trial to assess parotid-sparing 
IMRT in patients with HNSCC.
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Methods
Participants
We undertook a phase 3 randomised controlled trial at six 
UK radiotherapy centres (recruitment between Jan 21, 
2003, and Dec 7, 2007). Eligible patients had histologically 
conﬁ rmed HNSCC that arose from the oropharynx or 
hypopharynx and were to be treated by radiotherapy either 
primarily or postoperatively without concomitant 
chemotherapy. These patients were at high risk of radiation-
induced xerostomia—ie, if they were treated with 
conventional radiotherapy the estimated mean dose to 
both parotid glands would be greater than 24 Gy. Patients 
had WHO performance status 0 or 1 and any stage of 
disease except M1. Patients were required to attend regular 
follow-up, undergo salivary ﬂ ow measurements, and 
complete self-assessed QoL questionnaires.
Exclusion criteria included previous head or neck 
radiotherapy; previous malignancy except non-melanoma 
skin cancer; pre-existing salivary gland disease; tumour 
involvement of the parotid glands; or previous or 
concurrent illness that would compromise completion of 
treatment or follow-up. Prophylactic amifostine or 
pilocarpine was not permitted. Patients who had received 
neoadjuvant chemotherapy were eligible.
All patients provided written informed consent. 
PARSPORT (CRUK/03/005) was approved by the 
national South-West Multicentre Research Ethics 
Committee (MREC 03/6/79) and the local ethics 
committees of all participating centres. Our trial was 
sponsored by the Royal Marsden NHS Foundation Trust 
and undertaken in accordance with the principles of 
Good Clinical Practice.
Randomisation and masking
Patients were randomly assigned in a 1:1 ratio to parotid-
sparing IMRT or conventional radiotherapy (control). 
Independent randomisation was via telephone to the 
Clinical Trials and Statistics Unit at the Institute of 
Cancer Research (ICR-CTSU). Computer-generated 
random permuted blocks were used; stratiﬁ cation was by 
treatment centre and tumour site. Treatment allocation 
was not masked; however, the patient was not informed 
of the treatment until they had completed the baseline 
QoL questionnaires.
Procedures
Staging investigations included examination under 
anaesthetic, tumour biopsy, diagnostic CT or MRI of 
head and neck, chest radiograph, full blood count, and 
biochemistry. In postoperative patients, histology 
reports that documented the extent of surgical resection 
were required.
The protocol for target volume deﬁ nition and treatment 
planning has been previously described.9 All patients 
underwent CT-planned radiotherapy with either three-
dimensional conformal radiotherapy with parallel 
opposed lateral ﬁ elds (conventional radiotherapy) or 
parotid-sparing IMRT. The conventional radiotherapy 
regimen was the national standard of care in the UK and 
most other countries at the time our trial was designed. 
In both treatment groups, the primary tumour and 
involved lymph nodes were treated with 65 Gy in 30 daily 
fractions given Monday to Friday. 60 Gy in 30 fractions 
was delivered to postoperative patients unless there was 
macroscopic residual disease in which case 65 Gy in 
30 fractions was given. Nodal groups at risk of harbouring 
occult metastatic disease received a biologically equivalent 
dose of either 50 Gy in 25 daily fractions (conventional 
radiotherapy) or 54 Gy in 30 fractions (IMRT). For IMRT 
patients a planning constraint of less than 24 Gy to the 
whole contralateral parotid gland was used.9,10 For quality 
assurance, plans were assessed from all centres for 
protocol compliance and dosimetric consistency.10,11
Acute side-eﬀ ects were graded weekly with National 
Cancer Institute Common Toxicity Criteria (version 3)12 
during radiotherapy and until 8 weeks after treatment. 
Late radiotherapy side-eﬀ ects were assessed with the 
Late Eﬀ ects of Normal Tissues Subjective-Objective 
Management Analytic (LENT SOMA)13,14 and the Radiation 
Therapy Oncology Group (RTOG)15 scoring systems at 3, 
6, 12, 18, and 24 months after radiotherapy. Salivary ﬂ ow 
Figure 1: Study proﬁ le
IMRT=intensity-modulated radiotherapy.
94 patients recruited
47 randomly assigned to conventional 
radiotherapy
6 died before 12 months 6 died before 12 months
7 not assessed at 12 months
 3 withdrew consent
 2 did not attend
 1 reason unknown
 1 deviated and withdrew 
  (treated with chemoradiation)
2 not assessed at 12 months
 1 did not attend
 1 not done because of disease
  recurrence at 8 months
47 randomly assigned to IMRT
41 alive at 12 months 41 alive at 12 months
 29 alive and disease free 12 months
  after completion of radiotherapy
 5 alive with recurrence or progressive
  disease
37 alive and disease free 12 months
  after completion of radiotherapy
 2 alive with recurrence
 29 alive and disease free 24 months
  after completion of radiotherapy
 5 died
29 alive and disease free 24 months
  after completion of radiotherapy
 7 alive with recurrence or progressive
  disease
 3 died
34 evaluable for primary endpoint
at 12 months
 33 received treatment as per protocol
 1 deviation (IMRT given, unable to cover
  target volume adequately)
39 evaluable for primary endpoint
at 12 months
 37 received treatment as per protocol
 2 deviations (radiotherapy gap because of
  rectal bleeding, concomitant chemotherapy)
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measurements were done before radiotherapy, at week 4 
of radiotherapy, and at 2 weeks, 3, 6, 12, 18, and 24 months 
after radiotherapy. Unstimulated and sodium-citrate-
stimulated parotid saliva from each parotid duct oriﬁ ce 
and ﬂ oor of mouth saliva were collected by standard 
methods.7,8 After treatment, clinical follow-up was 
monthly in year 1, every 8 weeks in year 2, then every 
3–6 months until the end of year 5. Assessments were 
not blinded to treatment allocation.
Patient-reported QoL was collected with questionnaire 
booklets that contained the European Organization for 
Research and Treatment of Cancer (EORTC) QLQC30 
quality-of-life instrument16 (which measures generic 
cancer-related QoL), the associated head and neck speciﬁ c 
module HN35,17 and the modiﬁ ed xerostomia 
questionnaire.8 Patients completed the baseline booklet 
in the clinic before randomisation. Follow-up booklets 
were sent directly to the patients’ homes at 2 weeks, 3, 6, 
12, 18, and 24 months after radiotherapy.
Our primary objective was to assess late side-eﬀ ects. 
Our primary endpoint, agreed in discussion with the 
independent trial steering committee, was the proportion 
of patients with xerostomia of grade 2 or worse by the 
LENT SOMA subjective side-eﬀ ect scale 1 year after 
treatment. This endpoint was chosen because it assesses 
an abnormal symptom (ie, “partial but persistent or 
complete dryness” or worse) measured by a reliable and 
sensitive method for scoring late side-eﬀ ects in HNSCC.18 
We decided on 12 months a priori as a clinically 
appropriate time at which to make a valid assessment of 
late eﬀ ects.
Secondary endpoints were the proportion of patients 
with any measurable salivary ﬂ ow after radiotherapy, 
acute and other late radiation side-eﬀ ects, QoL that 
included xerostomia-related QoL as measured by the 
modiﬁ ed xerostomia questionnaire, locoregional 
progression-free survival (PFS), and overall survival. We 
deﬁ ned locoregional PFS as time from randomisation to 
locoregional recurrence or progressive disease as deﬁ ned 
by Response Evaluation Criteria in Solid Tumours.19 We 
deﬁ ned overall survival as time from randomisation to 
death from any cause.
Statistical analysis
Phase 2 studies had reported reduction in salivary ﬂ ow 
rates of 90% at 1–3 months compared with preradiotherapy 
rates with conventional therapy and of 40% with IMRT.7,20–22 
If we assume a 1-year xerostomia rate of 90% in the 
conventional radiotherapy group23 a sample size of 
84 patients is needed to detect a 30% absolute diﬀ erence in 
LENT SOMA of grade 2 or worse xerostomia between the 
study groups (90% power, 5% two-sided signiﬁ cance). In 
March, 2007, the independent data monitoring committee 
and the trial steering committee approved an increase in 
the target sample size to 84 evaluable patients (ie, alive 
1 year after the end of radiotherapy) that was anticipated to 
be achievable with 100 randomly assigned patients. In 
December, 2007, both committees approved closure of 
recruitment after 94 patients had been randomly assigned 
to the study groups with the expectation that this would 
provide suﬃ  cient evaluable patients to allow robust 
statistical analysis. Our trial was not powered to reliably 
assess small diﬀ erences in locoregional PFS or overall 
survival, although these are reported for completeness.
Our analysis was done on an intention-to-treat basis, 
with all patients who had a 12-month xerostomia 
assessment included. We compared the proportion of 
patients with grade 2 or worse xerostomia between groups 
with a χ² test. We assessed the sensitivity of results by 
repeating analyses of the primary endpoint with patients 
Conventional 
radiotherapy (n=47)
IMRT (n=47)
Mean age at randomisation (years) 57·3 (10·2; 37·5–82·8) 59·5 (9·2; 44·1–77·1)
Number of women 12 (26%) 14 (30%)
WHO performance status
0 42 (89%) 41 (87%)
1 5 (11%) 6 (13%)
Tumour site
Oropharynx 40 (85%) 40 (85%)
Hypopharynx 7 (15%) 7 (15%)
Tumour stage
T1 6 (13%) 6 (13%)
T2 27 (57%) 22 (47%)
T3 11 (23%) 16 (34%)
T4 3 (6%) 3 (6%)
Nodal stage
N0 16 (34%) 23 (49%)
N1 9 (19%) 15 (32%)
N2a 7 (15%) 2 (4%)
N2b 10 (21%) 6 (13%)
N2c 1 (2%) 0
N2 (unknown) 1 (2%) 1 (2%)
N3 3 (6%) 0
AJCC* stage
1 and 2 8 (17%) 15 (32%)
3 and 4 39 (83%) 32 (68%)
Neoadjuvant chemotherapy
Yes 19 (40%) 20 (43%)
No 28 (60%) 27 (57%)
Type of radiotherapy
Primary 32 (68%) 39 (83%)
Postoperative 15 (32%) 8 (17%)
Radiotherapy dose (Gy) 
Median dose to primary tumour and involved nodes 65·0 (65·0–65·0; 44) 65·0 (65·0–65·0; 47)
Median dose to elective nodes 50·0 (50·0–50·1; 43) 54·0 (54·0–54·1; 47)
Mean contralateral parotid dose† 61·0 (54·6–63·8; 43) 25·4 (23·2–28·0; 46)
Mean ipsilateral parotid dose† 61·0 (57·0–64·4; 43) 47·6 (39·9–54·5; 46)
Data are mean (SD; range),  n (%), or median (IQR; n). IMRT=intensity-modulated radiotherapy. *American Joint 
Committee on Cancer—groupings based on TNM staging data collected. †Mann-Whitney test p<0·0001.
Table 1: Baseline characteristics and treatment details
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censored 1 month before any disease recurrence, in case 
recurrence could adversely aﬀ ect salivary ﬂ ow, and by 
excluding patients whose side-eﬀ ect assessment was not 
within 2 months either side of its expected date. We have 
not presented these sensitivity analyses because they gave 
similar results to the main analysis. Odds of grade 2 or 
worse xerostomia at 12 and 24 months were calculated 
with a logistic-regression model. We present unadjusted 
odds ratios (ORs) and ORs adjusted for tumour site 
(oropharynx or hypopharynx), stage of disease (1 and 2 or 
3 and 4), and radiotherapy indication (radical or 
postoperative). All other analyses are unadjusted.
We compared the proportions of patients with any 
measurable saliva ﬂ ow and proportions ever reporting 
grade 2 or worse acute and late side-eﬀ ects between 
treatment groups with Fisher’s exact tests. For LENT 
SOMA scales, we used the maximum of the subjective, 
objective, management, and analytic component scores. 
We calculated CIs for diﬀ erences in proportion between 
groups with a normal approximation. To make some 
adjustment for multiple testing we used a signiﬁ cance 
level of 1% for all secondary side-eﬀ ects, sialometry, and 
QoL endpoints and accordingly we provide 99% CIs. Acute 
and late side-eﬀ ects in our report were those where side-
eﬀ ects of grade 2 or worse were experienced by at least 
20% of patients in either group or those where proportions 
were signiﬁ cantly diﬀ erent between treatment groups.
We calculated QoL scores with standard algorithms 
with a higher score suggesting poorer QoL on all scales 
except EORTC global health status, where a higher score 
suggests better QoL.24 We deemed diﬀ erences in EORTC 
QoL scores of 10 points or more clinically signiﬁ cant in 
line with EORTC guidelines.25 The primary QoL analysis 
included all completed questionnaires. We did a 
sensitivity analysis after censoring at 1 month before 
disease recurrence or progressive disease. We compared 
mean changes in EORTC QoL and xerostomia 
questionnaire item scores from baseline between groups 
by two-sample t tests.
We used generalised estimating equations (GEE), 
adjusting for the correlations in multiple measurements 
from the same patient (with an exchangeable correlation 
matrix) to account for the longitudinal nature of the 
xerostomia and QoL data. A pragmatic approach to 
modelling was taken, with treatment-by-time interaction 
terms included if they were identiﬁ ed in advance as 
clinically relevant or they were statistically signiﬁ cant. 
A GEE logistic regression model was ﬁ tted with 
xerostomia (grades 0 and 1 vs grades 2–4) as the response 
and allocated treatment, days since the completion of 
radiotherapy, and the interaction between the two as 
covariates. QoL GEE models also included terms for 
baseline score for the item of interest.
For survival-related endpoints, alive and disease-free 
patients were censored at date of last follow-up. We 
compared treatment groups with the log-rank test. 
Hazard ratios (HRs) with 95% CIs were obtained from 
Cox proportional hazards regression models with HRs of 
less than one favouring IMRT. The proportionality 
assumption of the Cox model held when tested with 
Schoenfeld residuals.
Figure 2: Proportion of patients reporting grade 2 or worse LENT SOMA subjective xerostomia and RTOG 
salivary gland side-eﬀ ects
p values quoted compare proportions with grade 2 or worse side-eﬀ ects in each group with a χ² test. Error bars 
represent 95% CIs. IMRT=intensity-modulated radiotherapy. LENT SOMA=Late Eﬀ ects of Normal Tissues 
Subjective-Objective Management Analytic. RTOG=Radiation Therapy Oncology Group.
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Our analyses were based on a database snapshot frozen 
on May 14, 2010, and were done in STATA version 10. 
ICR-CTSU had overall responsibility for trial coordination. 
Data collation, central statistical monitoring of data, and 
all interim and ﬁ nal analyses were performed at 
ICR-CTSU. The trial management group was responsible 
for the day to day running of the trial. The trial was 
overseen by an independent trial steering committee. 
The independent data monitoring committee regularly 
reviewed emerging safety and eﬃ  cacy data in conﬁ dence. 
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN48243537.
Role of the funding source
The funding source provided peer-reviewed approval for 
the trial but had no other role in study design, collection, 
analysis, interpretation of data, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication. JPM, RPA’H, and EH also had 
full access to all the data.
Results
Figure 1 shows the trial proﬁ le. We randomly allocated 
94 patients from six UK radiotherapy centres to treatment 
with either IMRT or conventional radiotherapy—47 patients 
to each group. One patient assigned to the conventional 
radiotherapy group was deemed ineligible because they 
were due to be treated with chemoradiation (no follow-up 
data are available for this patient). Table 1 shows the 
patient and tumour characteristics at baseline and 
treatment details. 39 patients (41%) received neoadjuvant 
chemo therapy (details of speciﬁ c chemotherapy drugs and 
doses were not collected). Mean dose to the whole 
Conventional radiotherapy IMRT
N Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 N Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Acute side-eﬀ ects*
Mucositis/stomatitis (clinical) 44 0 1 (2%) 16 (36%) 27 (61%) 0 46 1 (2%) 2 (4%) 14 (30%) 29 (63%) 0
Rash (dermatitis)† 44 0 3 (7%) 17 (39%) 24 (55%) 0 47 1 (2%) 9 (19%) 21 (45%) 15 (32%) 1 (2%)
Mucositis/stomatitis 
(functional/symptomatic)
39 1 (3%) 0 21 (54%) 17 (44%) 0 40 2 (5%) 3 (8%) 11 (28%) 24 (60%) 0
Dysphagia 44 0 1 (2%) 26 (59%) 17 (39%) 0 47 1 (2%) 6 (13%) 17 (36%) 23 (49%) 0
Pain 44 0 5 (11%) 23 (52%) 16 (36%) 0 47 1 (2%) 10 (21%) 19 (40%) 16 (34%) 1 (2%)
Fatigue‡ 44 0 26 (59%) 12 (27%) 6 (14%) 0 47 2 (4%) 10 (21%) 23 (49%) 12 (26%) 0
Xerostomia 44 0 4 (9%) 35 (80%) 5 (11%) ·· 47 0 14 (30%) 20 (43%) 13 (28%) ··
Salivary gland changes 44 0 2 (5%) 40 (91%) 2 (5%) 0 47 0 11 (23%) 30 (64%) 6 (13%) 0
Weight loss 40 2 (5%) 23 (58%) 14 (35%) 1 (3%) ·· 44 9 (20%) 14 (32%) 19 (43%) 2 (5%) ··
Hair loss/alopecia 44 14 (32%) 22 (50%) 8 (18%) 0 ·· 47 7 (15%) 27 (57%) 12 (26%) 1 (2%) ··
RTOG late side-eﬀ ects§
Salivary gland¶ 42 1 (2%) 3 (7%) 26 (62%) 12 (29%) 0 46 0 12 (26%) 32 (70%) 2 (4%) 0
Mucous membranes 42 1 (2%) 23 (55%) 17 (40%) 1 (2%) 0 46 4 (9%) 29 (63%) 12 (26%) 1 (2%) 0
Oesophagus 42 22 (52%) 11 (26%) 8 (19%) 1 (2%) 0 46 19 (41%) 17 (37%) 8 (17%) 2 (4%) 0
Joint (temporomandibular joint 
disorder)
42 22 (52%) 11 (26%) 9 (21%) 0 0 46 31 (67%) 11 (24%) 3 (7%) 1 (2%) 0
LENT SOMA late side-eﬀ ects§
Salivary gland‡,||
(xerostomia‡)
41 0
0
3 (7%)
3 (7%)
12 (29%)
19 (46%)
14 (34%)
14 (34%)
12 (29%)
5 (12%)
46 0
0
8 (17%)
8 (17%)
19 (41%)
31 (67%)
15 (33%)
4 (9%)
4 (9%)
3 (7%)
Mucosa** 41 1 (2%) 9 (22%) 17 (41%) 9 (22%) 5 (12%) 46 1 (2%) 19 (41%) 11 (24%) 11 (24%) 4 (9%)
Oesophagus††
(dysphagia)
41 15 (37%)
20 (49%)
15 (37%)
16 (39%)
4 (10%)
3 (7%)
5 (12%)
2 (5%)
2 (5%)
0
46 20 (43%)
21 (46%)
16 (35%)
16 (35%)
4 (9%)
5 (11%)
4 (9%)
3 (7%)
2 (4%)
1 (2%)
Skin‡‡ 41 5 (12%) 19 (46%) 11 (27%) 5 (12%) 1 (2%) 46 10 (22%) 24 (52%) 10 (22%) 2 (4%) 0
Larynx§§ 41 16 (39%) 15 (37%) 7 (17%) 2 (5%) 1 (2%) 46 16 (35%) 22 (48%) 8 (17%) 0 0
Mandible¶¶ 41 13 (32%) 16 (39%) 9 (22%) 3 (7%) 0 46 19 (41%) 11 (24%) 12 (26%) 3 (7%) 1 (2%)
Ear|||| 41 19 (46%) 12 (29%) 7 (17%) 3 (7%) 0 46 27 (59%) 13 (28%) 6 (13%) 0 0
Data are n (%). IMRT=intensity-modulated radiotherapy. RTOG=Radiation Therapy Oncology Group. LENT SOMA=Late Eﬀ ects of Normal Tissues Subjective-Objective Management Analytic. *Maximum 
Common Toxicity Criteria score during and up to 8 weeks post radiotherapy. †p for trend 0·01<p≤0·05. ‡p for trend 0·001<p≤0·01. §Maximum score between 3 and 24 months post radiotherapy. ¶p for trend 
p≤0·001. ||Worst of subjective (xerostomia), objective (saliva ﬂ ow), and management (xerostomia) grades. **Worst of subjective (pain, dysphagia, taste alteration), objective (mucosal integrity, weight), and 
management (pain, ulcer, dysphagia, taste alteration) grades. ††Worst of subjective (dysphagia, pain), objective (weight loss, stricture, ulceration, bleeding, anaemia), and management (dysphagia/stricture, 
weight loss, pain/ulceration, bleeding) grades. ‡‡Worst of subjective (roughness, sensation), objective (oedema, alopecia, pigmentation change, ulcer/necrosis, telangiectasia, ﬁ brosis/scar, atrophy/contraction), 
and management (dryness, sensation, ulcer, oedema, ﬁ brosis/scar) grades. §§Worst of subjective (pain, voice hoarseness, breathing), objective (oedema, mucosal integrity, respiration), and management (pain, 
hoarseness, respiration) grades. ¶¶Worst of subjective (pain, mastication, denture use, trismus), objective (exposed bone, trismus), and management (pain, bone, trismus/mastication) grades. ||||Worst of 
subjective (pain, tinnitus, hearing), objective (skin, hearing), and management (pain, skin, hearing loss) grades.
Table 2: Maximum acute and late side-eﬀ ect grades by treatment group
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contralateral parotid was signiﬁ cantly less in the IMRT 
group (p<0·0001; table 1). 45 of 47 patients randomly 
allocated to receive conventional radiotherapy and 45 of 
47 randomly assigned to receive IMRT completed 
radiotherapy as per protocol; 33 of the 34 patients evaluable 
for the primary outcome in the conventional radiotherapy 
group and 37 of 39 patients evaluable for the primary 
endpoint in the IMRT group completed radiotherapy as 
per protocol (ﬁ gure 1). Median follow-up in alive patients 
was 44·0 months (IQR 30·0–59·7).
At each timepoint from 3 to 24 months, a smaller 
proportion of IMRT patients reported grade 2 or worse 
LENT SOMA subjective xerostomia compared with 
conventional radiotherapy (ﬁ gure 2).
Of the 76 patients who had grade 2 or worse xerostomia 
during their follow-up, 62 (82%) ﬁ rst reported symptoms 
at 3 months: 33 (87%) of 38 patients in the conventional 
radiotherapy group versus 29 (76%) of 38 in the IMRT 
group. At 12 months, there were signiﬁ cantly fewer cases 
of xerostomia in the IMRT group (25 [74%, 95% CI 
56 to 87] of 34 in the conventional radiotherapy group vs 
15 [38%, 23 to 55] of 39 in the IMRT group), and the 
absolute reduction was 35% (95% CI 14 to 56; p=0·0027). 
At 24 months, 20 (83%, 63 to 95) of 24 patients in the 
conventional radiotherapy group reported xerostomia 
versus nine (29%, 14 to 48) of 31 in the IMRT group, and 
the absolute reduction was 54% (32 to 76; p<0·0001). 
These diﬀ erences equate to ORs of 0·23 (0·08 to 0·61) at 
12 months and 0·08 (0·02 to 0·31) at 24 months. 
Adjusted ORs were 0·23 (0·08 to 0·65) at 12 months and 
0·05 (0·01 to 0·26) at 24 months. Exploratory GEE 
analyses showed similar patterns to other analyses 
presented here (data not shown). The proportion of 
patients that reported grade 2 or worse xerostomia at 
12 months did not diﬀ er by tumour site, radiotherapy 
indication (primary vs postoperative), stage of disease, or 
use of neoadjuvant chemotherapy (data not shown). A 
similar pattern was seen over time and between 
treatment groups when xerostomia was scored with the 
RTOG scale (ﬁ gure 2).
Conventional radiotherapy IMRT
No measurable salivary ﬂ ow* 
(n=25)
Measurable salivary ﬂ ow 
(n=0)
No measurable salivary ﬂ ow 
(n=18)
Measurable salivary ﬂ ow 
(n=16)
Subjective xerostomia better than grade 2 6 (24%) 0 10 (56%) 12 (75%)
Subjective xerostomia grade 2 or worse 19 (76%) 0 8 (44%) 4 (25%)
Fisher’s exact test for association (treatment groups combined) p=0·018. LENT SOMA=Late Eﬀ ects of Normal Tissues Subjective-Objective Management Analytic. 
IMRT=intensity-modulated radiotherapy. *Measurable salivary ﬂ ow was deﬁ ned as any saliva collected from the Lashley cup apparatus.
Table 3: Concordance between unstimulated contralateral saliva ﬂ ow and LENT SOMA subjective xerostomia at 12 months
0
 Conventional radiotherapy 26 24 23 23 21 18
 IMRT 28 30 25 25 22 22
 Diﬀerence in mean 11·7 2·8 9·7 8·5 21·0 24·4
 (99% CI) (–14·4 to 37·8) (–18·4 to 24·0) (–13·5 to 32·9) (–15·9 to 33·0) (–8·9 to 50·9) (–4·3 to 53·2)
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Figure 3: Mean EORTC HN35 dry mouth subscale score changes from baseline
IMRT=intensity-modulated radiotherapy. EORTC HN35=European Organization for Research and Treatment of Cancer head and neck speciﬁ c module HN35.
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The only recorded acute adverse event of grade 2 or 
worse to diﬀ er between treatment groups (at the 1% 
signiﬁ cance level) was fatigue (table 2): 18 (41%; 99% CI 
23 to 61) of 44 patients in the conventional radiotherapy 
group versus 35 (74%; 55 to 89) of 47 in the IMRT group 
(p=0·0015). Of note, at 12 months, grade 3 or worse 
dysphagia was reported by two (5%) of 40 patients in the 
conventional radiotherapy group and four (9%) of 46 in 
the IMRT group.
We recorded baseline sialometry in 80 patients, all of 
whom had measurable salivary ﬂ ow. At 12 months 
unstimulated saliva ﬂ ow from the contralateral parotid 
gland was noted in 16 (47%) of 34 patients in the IMRT 
group compared with none of 25 in the conventional 
radiotherapy group (p<0·0001). Corresponding data at 
24 months were seven (44%) of 16 in the IMRT group 
versus none of 15 in the conventional radiotherapy group 
(p=0·0068). Signiﬁ cant diﬀ erences were also noted in 
stimulated saliva ﬂ ow from the contralateral parotid at 
12 months (p<0·0001). No signiﬁ cant diﬀ erences between 
the random assigned groups were seen in proportions 
with unstimulated or stimulated ﬂ ow from either the 
ipsilateral parotid or ﬂ oor of mouth. Strong concordance 
was noted between measurable contralateral saliva ﬂ ow 
and grade 2 or worse xerostomia (table 3).
Mean changes in global health status from baseline to 
12 months were 1·1 (99% CI –9·9 to 12·1) for conventional 
radiotherapy versus 3·0 (–11·9 to 17·9; p=0·78) for IMRT. 
Changes at 24 months were –2·8 (–17·1 to 11·6) for 
conventional radiotherapy versus 8·3 (–6·6 to 23·2) for 
IMRT, corresponding to a between group diﬀ erence in 
change scores of 11·1 (–9·0 to 31·2; p=0·14). No 
statistically signiﬁ cant diﬀ erences in change from 
baseline between groups were noted for any QLQC30 
subscale scores (data not shown).
In both study groups, HN35 subscale scores for dry 
mouth, senses, and sticky saliva were signiﬁ cantly 
worse than baseline at 12 months. Figure 3 shows mean 
increases from baseline from 2 weeks to 24 months in 
dry mouth subscale score, by treatment group. Mean 
increases from baseline at 12 months in the dry mouth 
subscale were 56·5 (99% CI 36·5 to 76·5; p<0·0001) for 
conventional radiotherapy and 48·0 (31·8 to 64·2; 
p<0·0001) for IMRT. Mean increases at 24 months 
were 59·3 (37·8 to 80·7; p<0·0001) for conventional 
radiotherapy and 34·8 (13·8 to 55·9; p<0·0001) for 
IMRT. At both time points, smaller score changes were 
noted in the IMRT group than in the conventional 
radiotherapy group, although these were not signiﬁ cant 
at the 1% level.
In the GEE model for dry mouth the main treatment 
coeﬃ  cient was –6·6 (99% CI –21·5 to 8·3; p=0·25) with 
a treatment-by-time interaction term of –0·03 (–0·06 to 
0·00; p=0·017), suggesting the diﬀ erence in dry mouth 
between treatment groups increases over time. Censoring 
at recurrence had a negligible eﬀ ect on QoL results, 
although the interaction term from the GEE analysis 
became less statistically signiﬁ cant (coeﬃ  cient –0·02; 
p=0·080).
The xerostomia questionnaire was only completed by 
39 patients at baseline and 12 months and by 33 patients 
at baseline and 24 months (compared with 73 reporting 
the primary endpoint at 12 months and 55 at 24 months). 
In both treatment groups all eight xerostomia 
questionnaire items were signiﬁ cantly worse at 12 and 
24 months than at baseline and although the changes 
were smaller in the IMRT group, no statistically 
signiﬁ cant diﬀ erences between group changes were 
noted (webappendix p 1).
Overall, there were seven locoregional recurrences in 
the conventional radiotherapy group: ﬁ ve in the high-
dose volume and two in both the high-dose volume and 
electively irradiated neck. In the IMRT group there were 
12 locoregional recurrences: 11 in the high-dose volume 
and one in the electively irradiated neck. No patients 
had a recurrence in the spared parotid tissue. 2-year 
locoregional PFS was 80% (95% CI 65 to 90) in the 
conventional radiotherapy group and 78% (62 to 87) in 
the IMRT group (absolute diﬀ erence 3%, 95% CI –15 to 
20; HR 1·53, 95% CI 0·63 to 3·70; log-rank p=0·34; 
ﬁ gure 4).
32 deaths have been reported so far (18 in the conventional 
radiotherapy group vs 14 in the IMRT group; HR for overall 
survival 0·68, 95% CI 0·34 to 1·37). Of these deaths, 
20 were due to head and neck cancer (ten in the 
conventional radiotherapy group vs ten in the IMRT 
Figure 4: Kaplan-Meier plot of locoregional progression-free survival by treatment group
Hazard ratio 1·53 (95% CI 0·63 to 3·70). Log-rank test p=0·34. 2-year locoregional progression-free survival 
estimates for conventional radiotherapy 80% (95% CI 65 to 90) and for IMRT 78% (62 to 87); absolute diﬀ erence 
3% (–15 to 20). IMRT=intensity-modulated radiotherapy.  
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group). Other causes of death in the conventional 
radiotherapy group were second (non-head-and-neck) 
primary cancer (four patients), cardiac (two), gastro-
intestinal complications (one), and suicide (one); and in 
the IMRT group were infection (two), second primary 
cancer (one), and gastrointestinal complications (one). 
Estimated 2-year overall survival was 76% (95% CI 60 to 86) 
with conventional radiotherapy and 78% (63 to 88) with 
IMRT (absolute diﬀ erence 2%, 95% CI –20 to 16).
Discussion
Our trial showed a signiﬁ cant reduction of radiation-
induced xerostomia for patients treated with IMRT 
compared with conventional radiotherapy by use of both 
LENT SOMA and RTOG scales. Furthermore, we showed 
recovery of saliva ﬂ ow by quantitative measurements, 
and improvements on QoL measures associated with 
xerostomia. To our knowledge our trial is the ﬁ rst to show 
that parotid-sparing IMRT reduces xerostomia in HNSCC 
(panel). A consistently higher QLQC30 Global and HN35 
dry mouth QoL score was reported in patients who 
received IMRT; between group diﬀ erences at 24 months 
were clinically but not statistically signiﬁ cant. Xerostomia 
questionnaire results showed changes in favour of IMRT 
in all eight questions but these diﬀ erences were not large 
enough to reach statistical signiﬁ cance, probably because 
of the small number of patients that completed this 
questionnaire. Although an association between 
measurable saliva ﬂ ow and presence of grade 2 or worse 
xerostomia was recorded, there was not perfect 
concordance. We postulate that this could be because of 
diﬀ erences in patient perception of the xerostomia 
symptom or because of other factors such as sub-
mandibular gland or oral cavity dose or comorbidity. 
Detailed analyses of the distribution of dose to the salivary 
tissue including parotid glands and other minor salivary 
glands, and its correlation with clinical outcomes are 
ongoing. Initial results suggest that there is no correlation 
between submandibular gland dose and xerostomia.
A limitation of our trial was that it was not possible to 
mask the treatments from patients or clinicians because 
of diﬀ erences in treatment delivery. However, results that 
relate to multiple secondary endpoints support the 
primary analysis and the size of the observed eﬀ ect is 
unlikely to be due entirely to assessment or reporting 
bias. After our trial was designed, several small non-
randomised studies29–35 and one case-control study36 of 
parotid-sparing IMRT have been published with a range 
of endpoints including saliva ﬂ ow rate, patient-reported 
symptoms, and QoL. These studies reported apparent 
improvements for IMRT over conventional radiotherapy. 
Two small single-institution randomised phase 3 trials of 
IMRT in nasopharyngeal cancer have also reported 
beneﬁ ts of IMRT over conventional radiotherapy. Pow 
and colleagues37 reported an increase in stimulated whole 
saliva ﬂ ow rate in patients receiving IMRT in a randomised 
trial of 51 patients with early-stage nasopharynx cancer. 
QoL was assessed with EORTC QLQC30, HN35, and the 
SF36 health survey and although QoL scores for some 
domains were better for IMRT patients, no improvements 
in patient-reported dry mouth symptoms on the HN35 
questionnaire were noted. Kam and colleagues38 reported 
a reduction in observer-rated severe xerostomia (RTOG 
grade 2 or worse) with IMRT (39% vs 82%; p=0·001) in 
60 patients with early-stage nasopharyngeal cancer. The 
results of the PARSPORT trial are thus likely to be 
generalisable to all head and neck tumours for which 
conventional radiotherapy is used.
In our study, fewer cases of acute dermatitis were 
recorded in patients treated with IMRT than in those 
treated with conventional radiotherapy, although 
diﬀ erences were not statistically signiﬁ cant at the 
1% level, probably because of reduced dose to skin. The 
proportions of patients that reported grade 2 or worse 
acute xerostomia and grade 2 or worse salivary gland 
changes also showed reductions, albeit not statistically 
signiﬁ cant (table 2). Late xerostomia side-eﬀ ects thus 
accord with acute side-eﬀ ects; this suggests that late 
radiation-induced xerostomia is a consequential eﬀ ect. 
We did not attempt to spare the submandibular or 
mucosal minor salivary glands within the planning 
target volume in our trial. It is possible that further 
reductions in severe xerostomia can be achieved by 
sparing these tissues, but this might risk underdosing 
crucial target tissues. Unexpectedly, acute fatigue was 
greater in patients treated with IMRT, which could be 
due to the greater radiation dose to non-tumour tissues. 
In an unplanned dosimetry review in a subset of patients, 
mean radiation doses to the posterior fossa were 
20–30 Gy in the patients treated with IMRT compared 
with about 6 Gy in patients treated with conventional 
Panel: Research in context
Systematic review
Intensity modulated radiotherapy (IMRT) allows focused 
radiation delivery to tumours. In patients with head and neck 
cancer it has been used to reduce the irradiation of salivary 
tissue to prevent radiation-induced xerostomia. Before the 
design of our randomised trial, a few small single centre 
experiences had been published and a review of the published 
work on IMRT had been done.26 No randomised trials were 
identiﬁ ed. During the recruitment period of the PARSPORT 
trial two smaller randomised trials were reported in 
nasopharyngeal cancer from centres in Asia, and several other 
single institutional experiences were reported.27,28
Interpretation
Our trial is the largest randomised trial of IMRT in head and 
neck cancer, and the only trial addressing squamous-cell 
carcinoma, the predominant form seen worldwide. Our trial 
shows that IMRT reduces patient-reported xerostomia, allows 
recovery of salivary ﬂ ow, and improves quality of life after 
treatment compared with conventional radiotherapy.
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radiotherapy, which could account for the recorded 
diﬀ erence in acute radiation fatigue. Late fatigue data 
were not collected because lethargy is not a recognised 
long-term side-eﬀ ect of radiotherapy. There was no 
signiﬁ cant association between the giving of neoadjuvant 
chemotherapy and either acute fatigue or xerostomia 
(data not shown). The addition of concurrent 
chemotherapy to altered fractionation radiotherapy 
remains experimental and was not used in our study. 
Further research is needed to establish the eﬀ ect of 
concurrent chemotherapy on xerostomia. Apart from 
salivary gland changes and radiation-induced xerostomia, 
other late side-eﬀ ects of conventional radiotherapy were 
not altered by IMRT.
Our trial was too small to detect small diﬀ erences in, or 
conclude non-inferiority of, locoregional PFS or overall 
survival. Although patients continue to be followed up 
for long-term survival, to show non-inferiority in overall 
survival to no more than 5% at 2 years (80% power, one-
sided 5% signiﬁ cance) would need a randomised 
controlled trial of more than 900 patients. In this, and 
other, head and neck IMRT studies most tumour 
recurrences happen within the high-dose volume. 
Recurrences have not been noted in the spared parotid 
tissue in patients treated with IMRT or surgery,21,39 
suggesting that a large study to show non-inferiority in 
this tumour type is probably both impractical and 
inappropriate. Our trial has shown a clinically and 
statistically signiﬁ cant reduction in xerostomia, improved 
salivary ﬂ ow, and improved QoL, and thus strongly 
supports a role for IMRT in HNSCC.
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